2011: keep calm and carry on
This article was originally published in Scrip
With all the commotion surrounding looming patent expiries, uncertainty still around US healthcare reforms, and the impact of economic austerity measures, it is not surprising that the pharmaceutical and biopharmaceutical sectors have lost some of their allure to generalist investors. However, with more than 7,000 delegates at this week's JP Morgan Healthcare conference, the industry's annual get together in San Francisco, many companies are in a much healthier position than may have been supposed.
You may also be interested in...
Cambridge, UK-based Healx has concluded a $56m series B round, led by Atomico, to put up to 50 potential rare disease treatments into the clinic within two years using its AI/ML platform.
Tapping into the ability of arenaviruses to deliver prolonged local immune activation, rapid regression of localized and metastatic cancers, and long-term disease control, Essen, Germany-based start-up Abalos Therapeutics has raised €12m to advance its lead candidates towards clinical testing.
Celgene agrees to pay $75m upfront for options to three Immatics TCR-T targets for solid tumors. Deal could be worth up to $1.59bn to the German biotech, which also retains option to co-develop and co-fund certain licensed products.